Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Distributes Free Second-Line Anti-HIV Drugs

This article was originally published in PharmAsia News

Executive Summary

China has begun distributing for free three anti-retroviral drugs as a second-line treatment for HIV patients. Two of the anti-HIV drugs are U.S.-made-Viread (tenofovir) by Gilead Sciences and Kaletra (lopinavir/ritonavir) by Abbott Laboratories. The Ministry of Health also is providing free doses of U.K.-based GlaxoSmithKline's Epivir (lamivudine), also known as 3TC, and used with other drugs as part of a first-line treatment. All three drugs cost more than $1,700 a year, double and triple the cost of first-line drugs. Ministry officials said an increasing number of HIV patients are developing resistance to first-line drugs and those in a trial saw their symptoms decline after six months on the second-line drugs. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel